Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00226122
Other study ID # INDO181202
Secondary ID 01
Status Completed
Phase Phase 4
First received September 23, 2005
Last updated June 24, 2010
Start date January 2003
Est. completion date December 2009

Study information

Verified date June 2010
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Denmark: National Board of Health
Study type Interventional

Clinical Trial Summary

Monosymptomatic nocturnal enuresis, defined as the involuntary loss of urine during the night at an age where voluntary bladder control should have been attained and on the background of normal urinary tract function, is a rather common disease of childhood with an estimated prevalence of 5-10% at tha age of 7 and a spontaneous remission rate of 15% per year.

The present study consists of two phases; an in-patient phase and an ambulatory phase.

In the in-patient phase we will examine the regulation of sodium and the circadian rhythm of the hormones that affect this regulation in children with enuresis nocturnal and healthy children, as well as the impact of indomethacin on renal water and electrolyte excretion.

In the ambulatory phase we will examine the efficacy and safety of a treatment modality consisting of a combination of dDAVP and indomethacin in patients with severe enuresis where dDAVP as monotherapy is inadequate.

A significant number of children with enuresis and nocturnal polyuria do not respond to treatment with dDAVP. If a combination treatment with dDAVP and indomethacin proves superior to dDAVP alone the regimen could readily be used in those difficult to cure cases of enuresis.


Description:

The "in-patient" phase is a comparative circadian study of three groups of participants and a non-placebo controlled study of the renal effects of indomethacin with special reference the renal handling of sodium.

The ambulatory phase is designed as a randomized double blind, crossover placebo controlled for indomethacin study of the efficacy and safety of a combination treatment with indomethacin and dDAVP.

In-patient phase: Primary effect parameters will be the diuresis, urinary osmolality, sodium excretion prior to and after the administration of indomethacin.

Secondary effect parameters will be the following: GFR, K+ excretion, creatinine excretion, urea excretion, as well as urinary concentrations of aquaporin 2 (AQP2), PGE2, AVP, URO, Na-transporter protein, concentration of renin, ANG II, ALDO, ANP, in plasma, prior to and after the administration of indomethacin.

Ambulatory phase: Primary effect parameter will be the number of dry nights achieved in the two treatment periods. Secondary effect parameters will be the nocturnal urine production, and the enuresis volumes In-patient phase: Day-night ratios will be calculated for all parameters tested. The circadian rhythm of hormones blood pressure and electrolyte excretion will be analyzed using COSINOR analysis.

The effect of indomethacin on the parameters tested will be compared to the basal measurements using student's t-test, ANOVA for repeated measurements or non-parametric tests. All statistical inference will take place on a "protocol population" basis.

Ambulatory phase: The efficacy of the combination treatment will be tested against placebo (only for indomethacin) with help of student's t-test, x2 test or non-parametric tests.

The results from the home recordings will be compared for the two treatment periods using non-parametric tests. The effect parameters that will undergo statistical analysis are the number of wet nights, the enuresis volume and the nocturnal urine production. The analysis will be on the basis of intention to treat population.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date December 2009
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 7 Years to 14 Years
Eligibility Inclusion Criteria:

- Monosymptomatic enuresis nocturnal

- At least 3 nights with enuresis per week

- Incomplete response to dDAVP

Exclusion Criteria:

- Daytime incontinence

- Urgency

- Frequency

- Other conditions that influence normal urine production

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Indomethacin
Indomethacin capsules 50 mg

Locations

Country Name City State
Denmark Dept of Pediatrics, Aarhus University Hospital Aarhus N Jutland

Sponsors (1)

Lead Sponsor Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Enuresis episodes 3 and 7 weeks No
Secondary Urine production, electrolyte excretion, hormonal changes 3 and 7 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02600676 - Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis N/A
Completed NCT02369445 - Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention N/A
Completed NCT01978210 - Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism N/A
Recruiting NCT06070675 - Comparison of a Paper and Automated Bladder Diary in Pediatric Patients N/A
Completed NCT01747343 - Toilet Training Toddlers and Preschoolers N/A
Recruiting NCT00437528 - Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity Phase 1
Recruiting NCT02699528 - The Effect of Methylphenidate on Primary Enuresis in Children With Attention Deficit Hyperactivity Disorder N/A
Withdrawn NCT01861145 - Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea Phase 4
Completed NCT04260646 - Alarm Treatment for Combined Enuresis and Daytime Urinary Incontinence in Children N/A
Completed NCT00270621 - Family Help Program: Nighttime Enuresis Treatment Program Phase 2
Completed NCT01367080 - A Study to Compare the Pharmacokinetic Profiles of Etravil® Tablet 10mg and Etravil® Tablet 25mg Phase 1
Completed NCT05190601 - Uroflowmetry in Children With Enuresis Nocturnal
Withdrawn NCT03478813 - Voiding School as a Treatment of Children's Day-time Incontinence or Enuresis N/A
Recruiting NCT03399877 - A Study on Accuracy Improvement of Repeated Measure Uroflowmetry- Electromyography N/A
Completed NCT01036841 - Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation Phase 4
Active, not recruiting NCT06185361 - Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis. N/A
Completed NCT04280887 - MyPad - Intelligent Bladder Pre-void Alerting System N/A
Completed NCT00240812 - A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting Phase 2